Eirini P Papapetrou

List of Publications by Year
in descending order

62	7,732	201674 27	149698 56
papers	citations	h-index	g-index

86	86	86	12764
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology, 2009, 27, 275-280.	17.5	3,047
2	Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature, 2009, 461, 402-406.	27.8	808
3	A bioinformatic assay for pluripotency in human cells. Nature Methods, 2011, 8, 315-317.	19.0	410
4	Safe harbours for the integration of new DNA in the human genome. Nature Reviews Cancer, 2012, 12, 51-58.	28.4	391
5	Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15163-15168.	7.1	389
6	Genomic safe harbors permit high Î²-globin transgene expression in thalassemia induced pluripotent stem cells. Nature Biotechnology, 2011, 29, 73-78.	17.5	277
7	Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12759-12764.	7.1	262
8	The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature, 2021, 592, 296-301.	27.8	236
9	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 2019, 36, 194-209.e9.	16.8	184
10	Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Molecular Therapy, 2016, 24, 678-684.	8.2	175
11	TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics, 2018, 50, 83-95.	21.4	156
12	Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nature Medicine, 2016, 22, 1392-1401.	30.7	131
13	Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology, 2015, 33, 646-655.	17.5	130
14	miR-371-3 Expression Predicts Neural Differentiation Propensity in Human Pluripotent Stem Cells. Cell Stem Cell, 2011, 8, 695-706.	11.1	126
15	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	11.1	114
16	A Genetic Strategy for Single and Combinatorial Analysis of miRNA Function in Mammalian Hematopoietic Stem Cells. Stem Cells, 2010, 28, 287-296.	3.2	77
17	Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nature Protocols, 2011, 6, 1251-1273.	12.0	67
18	A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Research, 2011, 39, e72-e72.	14.5	64

#	Article	IF	Citations
19	Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency. Cell Reports, 2012, 1, 99-109.	6.4	61
20	SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia, 2020, 34, 2525-2530.	7.2	61
21	Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. Journal of Clinical Investigation, 2009, 119, 157-68.	8.2	51
22	Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein. Scientific Reports, 2021, 11, 24432.	3.3	51
23	Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14057.	4.1	49
24	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	4.8	43
25	Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell, 2021, 28, 1074-1089.e7.	11.1	37
26	Induced pluripotent stem cells, past and future. Science, 2016, 353, 991-992.	12.6	34
27	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation, 2021, 144, 1940-1954.	1.6	33
28	Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. Cell Reports, 2020, 31, 107688.	6.4	31
29	Modeling blood diseases with human induced pluripotent stem cells. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	23
30	Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Molecular Therapy - Nucleic Acids, 2016, 5, e284.	5.1	21
31	MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood, 2022, 139, 205-216.	1.4	19
32	Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factorâ€“Mutant Neoplasms. Cancer Discovery, 2022, 12, 836-855.	9.4	19
33	Modeling myeloid malignancies with patient-derived iPSCs. Experimental Hematology, 2019, 71, 77-84.	0.4	18
34	Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. Nature Protocols, 2011, 6, 1274-1289.	12.0	12
35	Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. Blood Advances, 2021, 5, 687-699.	5.2	12
36	Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach. International Journal of Medical Sciences, 2010, 7, 94-100.	2.5	11

#	Article	IF	Citations
37	Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. Therapeutics and Clinical Risk Management, 2010, 6, 265.	2.0	10
38	Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells. JCI Insight, 2019, 4, .	5.0	10
39	A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. Cell Reports, 2014, 8, 1677-1685.	6.4	9
40	Reconstructing blood from induced pluripotent stem cells. F1000 Medicine Reports, 2010, 2, .	2.9	9
41	Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. Indian Journal of Pharmacology, 2011, 43, 385.	0.7	8
42	The Polycomb Group Protein L3MBTL1 Represses a SMAD5-Mediated Hematopoietic Transcriptional Program in Human Pluripotent Stem Cells. Stem Cell Reports, 2015, 4, 658-669.	4.8	7
43	Modeling Leukemia with Human Induced Pluripotent Stem Cells. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034868.	6.2	7
44	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Advances, 2022, 6, 2992-3005.	5.2	7
45	Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. Current Opinion in Hematology, 2021, 28, 50-56.	2.5	6
46	Gene and Cell Therapy for Î²-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. Advances in Experimental Medicine and Biology, 2017, 1013, 219-240.	1.6	5
47	Engineering of targeted megabase-scale deletions in human induced pluripotent stem cells. Experimental Hematology, 2020, 87, 25-32.	0.4	5
48	CARs Move To the Fast Lane. Molecular Therapy, 2014, 22, 477-478.	8.2	4
49	Studying leukemia stem cell properties and vulnerabilities with human iPSCs. Stem Cell Research, 2021, 50, 102117.	0.7	3
50	The Activated TGFÎ² Pathway in Shwachman Diamond Syndrome Impairs Hematopoiesis and Is Down-Regulated By Deletion of 7q. Blood, 2017, 130, 875-875.	1.4	3
51	FA iPS: correction or reprogramming first?. Blood, 2012, 119, 5341-5342.	1.4	2
52	Reprogramming and cancer. Stem Cell Research, 2021, 52, 102249.	0.7	2
53	Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses. Blood, 2016, 128, 962-962.	1.4	2
54	LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy - Nucleic Acids, 2016, 5, e394.	5.1	1

#	Article	IF	Citations
55	Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2021, 2185, 411-422.	0.9	1
56	Modeling myeloid malignancies with human induced pluripotent stem cells. Experimental Hematology, 2015, 43, S39.	0.4	0
57	Targeting a Novel Epigenetic Silencing Mechanism to Efficiently Upregulate Fetal Globin Gene Expression. Blood, 2011, 118, 352-352.	1.4	0
58	IPS Cells From Del(7q)-MDS Patients Display Impaired Proliferation and Hematopoietic Commitment. Blood, 2012, 120, 174-174.	1.4	0
59	An iPSC-Based Model Of MDS For Phenotype-Driven Gene and Drug Discovery. Blood, 2013, 122, 859-859.	1.4	0
60	Chromosome 7q Hemizygosity Recapitulates MDS-Related Cellular Phenotypes In Genetically Engineered Human Pluripotent Stem Cells. Blood, 2013, 122, 862-862.	1.4	0
61	Isogenic MDS-RS Patient-Derived iPSCs Define the Mis-Spliced Transcript Repertoire and Chromatin Landscape of SF3B1-Mutant Hematopoietic Stem/Progenitor Cells. Blood, 2021, 138, 147-147.	1.4	0
62	MDS/AML with del5q: An acquired â€œlaminopathyâ€?. Cell Stem Cell, 2022, 29, 498-499.	11.1	0